Almstead Neil Gregory, Chief Technical Operations Officer, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 53 transactions, Gregory has exclusively traded shares of PTC Therapeutics, Inc. (PTCT), with a total buy value of $4,984,275 and a total sell value of $13,197,127.50. Notably, his recent activity has been entirely focused on selling, with 20 transactions recorded since November 2025. These sales have ranged widely in value, from smaller transactions like $4,028.96 on January 7, 2026, to significant disposals such as $1,820,260.52 on November 25, 2025. The latter date marked a particularly active period, with multiple high-value sales exceeding $1 million each, including $1,572,544.48 and $1,115,580.70.
Gregory’s selling pattern has continued into 2026, with transactions on January 6, 7, and 8 involving amounts such as $98,419.05 and $67,352.45. More recent sales include $211,964.16 and $252,822.82 in February and March 2026, respectively. While some filings are marked as acquisitions (code "A") or mergers (code "M"), these entries show no monetary value, suggesting they may involve non-cash transactions or adjustments. Overall, Gregory’s trading history reveals a consistent trend of reducing his holdings in PTCT, with no recent purchases to offset the substantial volume of sales. This activity underscores a significant divestment strategy, though the specific reasons behind these transactions remain undisclosed.
AI-assisted summary